| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -50.7 | -28.5 |
| Net income | -50.7 | -28.5 |
| EPS (diluted, $ a share) | $-1.23 | $-14.77 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: OBX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Obsidian Therapeutics, Inc.: key numbers
- Share price
- $12.36Close, Nov 16
- Market cap
- $764M
- Shares outstanding
- 61.77MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Obsidian Therapeutics, Inc.
All →Obsidian Therapeutics Financial Results
Obsidian Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $324.4 million following its Nasdaq debut and a $350 million financing. The company is advancing its lead TIL cell therapy candidate, amsoki-cel, with enrollment in a registration-enabling melanoma cohort expected to complete in Q1 2027.
- Term
- 3 years
“2026 has been a transformative year so far for Obsidian. In the third quarter, we closed an oversubscribed $350 million financing, completed our transaction with Galera Therapeutics, and debuted on Nasdaq as a publicly traded company.”
Madan Jagasia, M.D., Chief Executive Officer
“The updated data we presented at SITC further strengthen our belief in the program, highlighting amsoki-cel’s consistent, favorable safety profile and encouraging clinical activity in patients with advanced melanoma, including an objective response rate of 67%, median progression-free survival of 8.3 months, and median duration of response not yet reached at median study follow-up of 14.3 months.”
Madan Jagasia, M.D., Chief Executive Officer